Alexa
  • Directory of Taiwan

Serono says it won global rights to Newron's Parkinson's Disease treatment

Serono says it won global rights to Newron's Parkinson's Disease treatment

Swiss drugmaker Serono SA said Monday it won worldwide rights to develop Newron Pharmaceuticals SpA's safinamide Parkinson's disease treatment.
Serono will become responsible for future development and manufacturing costs and will make upfront and additional payments of as much as US$200 million (euro159.9 million), the company said in a statement. The company will also pay Newron undisclosed royalties on worldwide net sales.
Other details of the financial terms were not disclosed.
Newron recently reported positive results with safinamide from an early Phase III study in Parkinson's disease, Serono said in a statement.
"This partnership enables us to expand our neurology portfolio by investing in innovative products to meet significant unmet medical needs, such as Parkinson's and Alzheimer's disease," said Franck Latrille, Serono's senior executive vice president for global product development.


Updated : 2021-10-25 14:57 GMT+08:00